These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 22733396)

  • 1. Lenalidomide enhances anti-myeloma cellular immunity.
    Luptakova K; Rosenblatt J; Glotzbecker B; Mills H; Stroopinsky D; Kufe T; Vasir B; Arnason J; Tzachanis D; Zwicker JI; Joyce RM; Levine JD; Anderson KC; Kufe D; Avigan D
    Cancer Immunol Immunother; 2013 Jan; 62(1):39-49. PubMed ID: 22733396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma.
    Vo MC; Anh-NguyenThi T; Lee HJ; Nguyen-Pham TN; Jaya Lakshmi T; Jung SH; Kim HJ; Lee JJ
    Exp Hematol; 2017 Feb; 46():48-55. PubMed ID: 27889516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
    Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
    Front Immunol; 2018; 9():1798. PubMed ID: 30123221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of thalidomide and its analogues: implications for anticancer therapy.
    Teo SK
    AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.
    Noonan K; Rudraraju L; Ferguson A; Emerling A; Pasetti MF; Huff CA; Borrello I
    Clin Cancer Res; 2012 Mar; 18(5):1426-34. PubMed ID: 22241792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.
    Rosenblatt J; Glotzbecker B; Mills H; Vasir B; Tzachanis D; Levine JD; Joyce RM; Wellenstein K; Keefe W; Schickler M; Rotem-Yehudar R; Kufe D; Avigan D
    J Immunother; 2011 Jun; 34(5):409-18. PubMed ID: 21577144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.
    Neuber B; Herth I; Tolliver C; Schoenland S; Hegenbart U; Hose D; Witzens-Harig M; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunol; 2011 Jul; 187(2):1047-56. PubMed ID: 21677134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.
    Hsu AK; Quach H; Tai T; Prince HM; Harrison SJ; Trapani JA; Smyth MJ; Neeson P; Ritchie DS
    Blood; 2011 Feb; 117(5):1605-13. PubMed ID: 20978269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
    Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
    Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
    Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
    Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.
    Busch A; Zeh D; Janzen V; Mügge LO; Wolf D; Fingerhut L; Hahn-Ast C; Maurer O; Brossart P; von Lilienfeld-Toal M
    Clin Exp Immunol; 2014 Aug; 177(2):439-53. PubMed ID: 24712857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
    Ray A; Tian Z; Das DS; Coffman RL; Richardson P; Chauhan D; Anderson KC
    Leukemia; 2014 Aug; 28(8):1716-24. PubMed ID: 24476765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
    Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
    Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
    Paiva B; Mateos MV; Sanchez-Abarca LI; Puig N; Vidriales MB; López-Corral L; Corchete LA; Hernandez MT; Bargay J; de Arriba F; de la Rubia J; Teruel AI; Giraldo P; Rosiñol L; Prosper F; Oriol A; Hernández J; Esteves G; Lahuerta JJ; Bladé J; Perez-Simon JA; San Miguel JF;
    Blood; 2016 Mar; 127(9):1151-62. PubMed ID: 26668134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas.
    Sakamaki I; Kwak LW; Cha SC; Yi Q; Lerman B; Chen J; Surapaneni S; Bateman S; Qin H
    Leukemia; 2014 Feb; 28(2):329-37. PubMed ID: 23765229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
    Galustian C; Meyer B; Labarthe MC; Dredge K; Klaschka D; Henry J; Todryk S; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB; Dalgleish AG
    Cancer Immunol Immunother; 2009 Jul; 58(7):1033-45. PubMed ID: 19009291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
    Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
    Benson DM; Bakan CE; Zhang S; Collins SM; Liang J; Srivastava S; Hofmeister CC; Efebera Y; Andre P; Romagne F; Bléry M; Bonnafous C; Zhang J; Clever D; Caligiuri MA; Farag SS
    Blood; 2011 Dec; 118(24):6387-91. PubMed ID: 22031859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model.
    Vo MC; Nguyen-Pham TN; Lee HJ; Jaya Lakshmi T; Yang S; Jung SH; Kim HJ; Lee JJ
    Oncotarget; 2017 Apr; 8(16):27252-27262. PubMed ID: 28460478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
    Gribben JG; Fowler N; Morschhauser F
    J Clin Oncol; 2015 Sep; 33(25):2803-11. PubMed ID: 26195701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.